RxDoctor Payments DataLook up a doctor →

Norman Lepor, MD

Cardiology · Beverly Hills, CANPI 1013979673

Payments from drug & device makers

$7,126,912in general payments, 2019–2025

Across 2,863 payments — averaging $2489.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.7M
  • Amgen$1.2M
  • AstraZeneca$690K
  • Eli Lilly$503K
  • Bayer$379K
  • Regeneron$286K
  • plus $2.4M from 54 others
$145,689in research payments, 2019–2025

Across 22 payments — averaging $6622.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Applied Therapeutics, Inc.$78K
  • Eli Lilly$42K
  • Amgen$15K
  • Novartis$10K
  • Novo Nordisk AS$733

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis266$1,698,009
Amgen219$1,189,514
AstraZeneca199$689,622
Eli Lilly36$503,346
Bayer199$379,450
Regeneron32$285,656
Boehringer Ingelheim244$281,798
Lilly USA, LLC156$201,040
Merck198$194,794
Novo Nordisk AS95$194,546
Sanofi US Services Inc.35$172,302
Esperion Therapeutics, Inc.217$165,446
Sanofi-aventis U.S. LLC80$157,205
American Regent19$142,161
Novo Nordisk111$132,588
Ortho-clinical Diagnostics, Inc.3$113,623
Amarin Pharma, Inc.128$106,429
Astrazeneca UK Limited9$100,700
Regeneron Healthcare Solutions, Inc.83$75,683
Ionis Pharmaceuticals, Inc.18$67,665
Lexicon Pharmaceuticals, Inc.67$59,133
Pfizer85$54,251
Kiniksa Pharmaceuticals, Ltd.53$48,197
Applied Therapeutics, Inc.4$26,403
Boehringer Ingelheim Pharma GmbH & Co.kg5$21,700
Corcept Therapeutics22$20,100
Vifor Pharma, Inc.10$13,318
E.r. Squibb & Sons, L.L.C.49$7,470
Agepha Pharma FZ LLC5$4,422
Idorsia Pharmaceuticals US Inc1$3,540
Daiichi Sankyo Inc.4$3,425
Kiniksa Pharmaceuticals International, PLC7$2,632
Medtronic(2 entities)30$2,505
Bridgebio Pharma, Inc.5$2,130
Boehringer Ingelheim International GmbH15$1,832
Johnson & Johnson34$729
Alnylam Pharmaceuticals Inc.26$721
Abbott6$389
Boston Scientific12$376
Edwards Lifesciences9$250
Novartis Pharma AG2$187
Currax Pharmaceuticals LLC11$169
Kestra Medical Technology Services, Inc.6$153
Scpharmaceuticals Inc.1$135
Eisai Inc.2$130
Biosense Webster, Inc.1$125
Heartflow, Inc.5$123
Arbor Pharmaceuticals, Inc.7$119
Impulse Dynamics (USA) Inc.3$110
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$90
Actelion Pharmaceuticals US, Inc.5$85
Takeda Pharmaceuticals U.S.A., Inc.4$70
Kowa Pharmaceuticals America, Inc.3$49
Astrazeneca AB2$40
Medicure Pharma Inc.2$36
Bsn Medical Inc1$35
Philips North America LLC1$25
Aegerion Pharmaceuticals, Inc.1$23
Biohaven Pharmaceutical Holding Company Ltd.1$23
Otsuka America Pharmaceutical, Inc.1$22

How this compares

$7,126,912 in reported general payments places this provider in the 95th percentile of 156 cardiology providers in California.

See all cardiology providers in California →

Medicare billing

Part B allowed, 2024
$2,070,815
Medicare patients
1,921
Services billed
77,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiology in Beverly Hills

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →